CalciMedica was founded in December 2006 by Gonul Velicelebi, Ph.D.,  Kenneth Stauderman, Ph.D. and Jack Roos, Ph.D., all previously with TorreyPines Therapeutics, where they discovered the role of STIM1 in the Icrac pathway in 2003. Other co-founders, all from the CBR Institute, include Anjana Rao, Ph.D., Patrick Hogan, Ph.D. and Stefan Feske, M.D, who identified Orai1 as the CRAC channel subunit in 2006. CalciMedica has acquired exclusive rights to both STIM1 and Orai1 to pursue the discovery of novel CRAC channel inhibitors for treating autoimmune diseases and organ transplant rejection. Michael Harpold, Ph.D., and Tom Reed, MBA, both previously with SIBIA Neurosciences, are also co-founders and provide valuable input on intellectual property and corporate matters. 

CalciMedica received its initial financing from SR One in December 2006 and closed Series A in July 2007. Series B was led by Sanderling Ventures, with participation from SR One, and closed in August 2007.